Using light to treat Alzheimer's disease
News Nov 15, 2015
Medical application of photoactive chemicals offers a promising therapeutic strategy for neurodegenerative diseases.
A Korean research team jointly led by Professor Chan Beum Park of the Materials Science and Engineering Department at Korea Advanced Institute of Science and Technology (KAIST) and Dr. Kwon Yu from the Bionano Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) conducted research to suppress an abnormal assembly of beta-amyloids, a protein commonly found in the brain, by using photo-excited porphyrins.
Beta-amyloid plaques are known to cause Alzheimer's disease. This research finding suggests new ways to treat neurodegenerative illnesses including Alzheimer's disease. It was published online as the lead article in the September 21th issue of Angewandte Chemie.
Light-induced treatments using organic photosensitizers have advantages to managing the treatment in time and area. In the case of cancer treatments, doctors use photodynamic therapies where a patient is injected with an organic photosensitizer, and a light is shed on the patient's lesion. However, such therapies had never been employed to treat neurodegenerative diseases.
Alzheimer's starts when a protein called beta-amyloid is created and deposited in a patient's brain. The abnormally folded protein created this way harms the brain cells by inducing the degradation of brain functions, for example, dementia. If beta-amyloid creation can be suppressed at an early stage, the formation of amyloid deposits will stop. This could prevent Alzheimer's disease or halt its progress.
The research team effectively prevented the buildup of beta-amyloids by using blue LED lights and a porphyrin inducer, which is a biocompatible organic compound. By absorbing light energy, a photosensitizer such as porphyrin reaches the excitation state. Active oxygen is created as the porphyrin returns to its ground state. The active oxygen oxidizes a beta-amyloid monomer, and by combining with it, disturbs its assembly.
Deposits of beta-amyloid in fruit flies stopped by using porphyrin and blue LED lights. Credit: KAIST / BI Lee et al., Angewandte Chemie, 2015
The technique was tested on drosophilae which were produced to model Alzheimer on invertebrates. The research showed that symptoms of Alzheimer's disease in the fruit flies such as damage on synapse and muscle, neuronal apoptosis, degradation in motility, and decreased longevity were alleviated. Treatments with light provide additional benefits: less medication is needed than other drug treatments, and there are fewer side effects. When developed, photodynamic therapy will be used widely for this reason.
Professor Park said, "This work has significance as it was the first case to use light and photosensitizers to stop deposits of beta-amyloids. We plan to carry the research further by testing compatibility with other organic and inorganic photosensitizers and by changing the subject of photodynamic therapy to vertebrate such as mice."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Lee BI et al. Photoexcited Porphyrins as a Strong Suppressor of β-Amyloid Aggregation and Synaptic Toxicity. Angewandte Chemie, first published July 14 2015. doi: 10.1002/anie.201504310
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Vegetable Compound Could Have a Key Role in ‘Beeting’ Alzheimer’s DiseaseNews
A compound in beets that gives the vegetable its distinctive red color could eventually help slow the accumulation of misfolded proteins in the brain, a process that is associated with Alzheimer’s disease.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018